AAV plasmid DNA simplifies liver-directed in vivo gene therapy: Comparison of expression levels after plasmid DNA-, adeno-associated virus- and adenovirus-mediated liver transfection

Journal of Gene Medicine

Volumn 12, Issue 10, 2010, Pages 810-817

  Doenecke, Axel ^a   Krömer, Alexander ^a   Scherer, Marcus N ^a   Schlitt, Hans Jürgen ^a   Geissler, Edward K ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

AAV plasmid; in vivo gene therapy; Naked DNA gene transfer; Nonviral gene transfer

Indexed keywords

ADENOVIRUS VECTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PARVOVIRUS VECTOR; PLASMID DNA; RT1 A ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIAC GRAFT REJECTION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; EMBRYO; GENE EXPRESSION; GENETIC TRANSFECTION; HEART TRANSPLANTATION; HUMAN; HUMAN CELL; HYDRODYNAMICS; IN VIVO GENE TRANSFER; INVERTED TERMINAL REPEAT; LIVER; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; DEPENDOVIRUS; DNA, VIRAL; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HUMANS; HYDRODYNAMICS; LIVER; MALE; PLASMIDS; RATS; RATS, INBRED LEW; TERMINAL REPEAT SEQUENCES; TRANSFECTION;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; ANIMALIA; RATTUS; RODENTIA;

EID: 77958559564     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1498     Document Type: Article

References (66)

1. Nomura M, Yamashita K, Murakami M, et al. Induction of donor-specific tolerance by adenovirus-mediated CD40Ig gene therapy in rat liver transplantation. Transplantation 2002; 73: 1403-1410.
2. Schmitz V, Barajas M, Wang L, et al. Adenovirus-mediated CD40 ligand gene therapy in a rat model of orthotopic hepatocellular carcinoma. Hepatology 2001; 34: 72-81.
3. Yang Z, Wu X, Tsui TY, Hou Y, Luk JM, Fan ST. Long-term liver allograft survival induced by combined treatment with rAAV-hCTLA4Ig gene transfer and low-dose FK506. Transplantation 2003; 75: 303-308.
4. Yang ZF, Wu XB, Tsui TY, Hou YD, Luk JM, Fan ST. Recombinant adeno-associated virus vector: is it ideal for gene delivery in liver transplantation? Liver Transpl 2003; 9: 411-420.
5. Herzog RW, Cao O, Srivastava A. Two decades of clinical gene therapy-success is finally mounting. Discov Med 2010; 9: 105-111.
6. Tan PH, Janes SE, Handa AI, Friend PJ. More trouble ahead; is gene therapy coming of age? Expert Opin Biol Ther 2008; 8: 561-567.
7. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 2003; 4: 346-358.
8. Waehler R, Russell SJ, Curiel DT. Engineering targeted viral vectors for gene therapy. Nat Rev Genet 2007; 8: 573-587.
9. Li SD, Huang L. Gene therapy progress and prospects: non-viral gene therapy by systemic delivery. Gene Ther 2006; 13: 1313-1319.
10. Inoue S, Hakamata Y, Kaneko M, Kobayashi E. Gene therapy for organ grafts using rapid injection of naked DNA: application to the rat liver. Transplantation 2004; 77: 997-1003.
11. Graeb C, Justl M, Scherer MN, et al. Expression of high levels of soluble allogeneic major histocompatability complex class I antigen by adenoviral gene transfer strongly inhibits allospecific cytotoxic T lymphocytes in vivo. Transplant Proc 2002; 34: 1398-1399.
12. Herweijer H, Wolff JA. Gene therapy progress and prospects: hydrodynamic gene delivery. Gene Ther 2007; 14: 99-107.
13. Hodges BL, Taylor KM, Joseph MF, Bourgeois SA, Scheule RK. Long-term transgene expression from plasmid DNA gene therapy vectors is negatively affected by CpG dinucleotides. Mol Ther 2004; 10: 269-278.
14. Ponder KP. Gene therapy for haemophilia. Curr Opin Hematol 2006; 13: 301-307.
15. Budker VG, Subbotin VM, Budker T, Sebestyen MG, Zhang G, Wolff JA. Mechanism of plasmid delivery by hydrodynamic tail vein injection. II. Morphological studies. J Gene Med 2006; 8: 874-888.
16. Sebestyen MG, Budker VG, Budker T, et al. Mechanism of plasmid delivery by hydrodynamic tail vein injection. I. Hepatocyte uptake of various molecules. J Gene Med 2006; 8: 852-873.
17. Wolff JA, Budker V. The mechanism of naked DNA uptake and expression. Adv Genet 2005; 54: 3-20.
18. Zhang G, Budker VG, Ludtke JJ, Wolff JA. Naked DNA gene transfer in mammalian cells. Methods Mol Biol 2004; 245: 251-264.
19. Grieger JC, Samulski RJ. Adeno-associated virus as a gene therapy vector: vector development, production and clinical applications. Adv Biochem Eng Biotechnol 2005; 99: 119-145.
20. Grimm D, Kay MA. From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr Gene Ther 2003; 3: 281-304.
21. High K. AAV-mediated gene transfer for haemophilia. Genet Med 2002; 4: 56S-61S.
22. Wang L, Herzog RW. AAV-mediated gene transfer for treatment of haemophilia. Curr Gene Ther 2005; 5: 349-360.
23. Doenecke A, Frank E, Scherer MN, Schlitt HJ, Geissler EK. Prolongation of heart allograft survival after long-term expression of soluble MHC class I antigens and vIL-10 in the liver by AAV-plasmid-mediated gene transfer. Langenbecks Arch Surg 2008; 393: 343-348.
24. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95: 2509-2514.
25. Nyberg-Hoffman C, Shabram P, Li W, Giroux D, Aguilar-Cordova E. Sensitivity and reproducibility in adenoviral infectious titer determination. Nat Med 1997; 3: 808-811.
26. Walsh CE, Liu JM, Xiao X, Young NS, Nienhuis AW, Samulski RJ. Regulated high level expression of a human gamma-globin gene introduced into erythroid cells by an adeno-associated virus vector. Proc Natl Acad Sci USA 1992; 89: 7257-7261.
27. Geissler EK, Wang J, Fechner JH, Jr., Burlingham WJ, Knechtle SJ. Immunity to MHC class I antigen after direct DNA transfer into skeletal muscle. J Immunol 1994; 152: 413-421.
28. Auricchio A, Hildinger M, O'Connor E, Gao GP, Wilson JM. Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. Hum Gene Ther 2001; 12: 71-76.
29. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998; 72: 2224-2232.
30. Girod A, Ried M, Wobus C, et al. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat Med 1999; 5: 1052-1056.
31. Clark KR, Liu X, McGrath JP, Johnson PR. Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses. Hum Gene Ther 1999; 10: 1031-1039.
32. Ono K, Lindsey ES. Improved technique of heart transplantation in rats. J Thorac Cardiovasc Surg 1969; 57: 225-229.
33. Graeb C, Justl M, Scherer MN, et al. Use of an adenoviral vector to express soluble donor-major histocompatibility complex molecules capable of suppressing the immune response in rat transplant recipients. Hum Immunol 2002; 63: 844-852.
34. Geissler EK, Scherer MN, Graeb C. Soluble donor MHC class I gene transfer to thymus promotes allograft survival in a high-responder heart transplant model. Transpl Int 2000; 13(Suppl 1): S452-S455.
35. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999; 6: 1258-1266.
36. de Roos WK, Fallaux FJ, Marinelli AW, et al. Isolated-organ perfusion for local gene delivery: efficient adenovirus-mediated gene transfer into the liver. Gene Ther 1997; 4: 55-62.
37. Morral N, O'Neal W, Rice K, et al. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci USA 1999; 96: 12816-12821.
38. Snyder RO, Miao CH, Patijn GA, et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 1997; 16: 270-276.
39. Xiao W, Berta SC, Lu MM, Moscioni AD, Tazelaar J, Wilson JM. Adeno-associated virus as a vector for liver-directed gene therapy. J Virol 1998; 72: 10222-10226.
40. Davidoff AM, Gray JT, Ng CY, et al. Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Mol Ther 2005; 11: 875-888.
41. Brunetti-Pierri N, Palmer DJ, Mane V, et al. Increased hepatic transduction with reduced systemic dissemination and proinflammatory cytokines following hydrodynamic injection of helper-dependent adenoviral vectors. Mol Ther 2005; 12: 99-106.
42. Takekubo M, Tsuchida M, Haga M, et al. Hydrodynamics-based delivery of plasmid DNA encoding CTLA4-Ig prolonged cardiac allograft survival in rats. J Gene Med 2007; 10: 290-297.
43. Zhang G, Song YK, Liu D. Long-term expression of human alpha1-antitrypsin gene in mouse liver achieved by intravenous administration of plasmid DNA using a hydrodynamics-based procedure. Gene Ther 2000; 7: 1344-1349.
44. Ochiai H, Harashima H, Kamiya H. Intranuclear disposition of exogenous DNA in vivo: silencing, methylation and fragmentation. FEBS Lett 2006; 580: 918-922.
45. Alino SF, Crespo A, Dasi F. Long-term therapeutic levels of human alpha-1 antitrypsin in plasma after hydrodynamic injection of nonviral DNA. Gene Ther 2003; 10: 1672-1679.
46. Miao CH, Ye X, Thompson AR. High-level factor VIII gene expression in vivo achieved by nonviral liver-specific gene therapy vectors. Hum Gene Ther 2003; 14: 1297-1305.
47. Chen ZY, He CY, Ehrhardt A, Kay MA. Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther 2003; 8: 495-500.
48. Chen ZY, He CY, Meuse L, Kay MA. Silencing of episomal transgene expression by plasmid bacterial DNA elements in vivo. Gene Ther 2004; 11: 856-864.
49. Hackett PB, Ekker SC, Largaespada DA, McIvor RS. Sleeping beauty transposon-mediated gene therapy for prolonged expression. Adv Genet 2005; 54: 189-232.
50. Masuda K, Yamamoto S, Endoh M, Kaneda Y. Transposon-independent increase of transcription by the Sleeping Beauty transposase. Biochem Biophys Res Commun 2004; 317: 796-800.
51. Mikkelsen JG, Yant SR, Meuse L, Huang Z, Xu H, Kay MA. Helper-Independent Sleeping Beauty transposon-transposase vectors for efficient nonviral gene delivery and persistent gene expression in vivo. Mol Ther 2003; 8: 654-665.
52. Piechaczek C, Fetzer C, Baiker A, Bode J, Lipps HJ. A vector based on the SV40 origin of replication and chromosomal S/MARs replicates episomally in CHO cells. Nucleic Acids Res 1999; 27: 426-428.
53. Jenke AC, Stehle IM, Herrmann F, et al. Nuclear scaffold/matrix attached region modules linked to a transcription unit are sufficient for replication and maintenance of a mammalian episome. Proc Natl Acad Sci USA 2004; 101: 11322-11327.
54. Nakai H, Yant SR, Storm TA, Fuess S, Meuse L, Kay MA. Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol 2001; 75: 6969-6976.
55. Conlon TJ, Cossette T, Erger K, et al. Efficient hepatic delivery and expression from a recombinant adeno-associated virus 8 pseudotyped alpha1-antitrypsin vector. Mol Ther 2005; 12: 867-875.
56. Nakai H, Montini E, Fuess S, et al. Helper-independent and AAV-ITR-independent chromosomal integration of double-stranded linear DNA vectors in mice. Mol Ther 2003; 7: 101-111.
57. Wang J, Xie J, Lu H, et al. Existence of transient functional double-stranded DNA intermediates during recombinant AAV transduction. Proc Natl Acad Sci USA 2007; 104: 13104-13109.
58. Fabre JW, Grehan A, Whitehorne M, et al. Hydrodynamic gene delivery to the pig liver via an isolated segment of the inferior vena cava. Gene Ther 2008; 15: 452-462.
59. Yoshino H, Hashizume K, Kobayashi E. Naked plasmid DNA transfer to the porcine liver using rapid injection with large volume. Gene Ther 2006; 13: 1696-1702.
60. Brunetti-Pierri N, Stapleton GE, Law M, et al. Efficient, long-term hepatic gene transfer using clinically relevant HDAd doses by balloon occlusion catheter delivery in nonhuman primates. Mol Ther 2009; 17: 327-333.
61. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in haemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006; 12: 342-347.
62. Danos O. AAV gene vector manufacturing: what is feasible now and in the near future? Workshop. 24 June 2006; Méridien Beach Plaza Hotel, Monte Carlo, 2006.
63. Hebel H, Attra H, Khan A, Draghia-Akli R. Successful parallel development and integration of a plasmid-based biologic, container/closure system and electrokinetic delivery device. Vaccine 2006; 24: 4607-4614.
64. Watson R. The Vector Directory: An Analysis of International GMP Gene Therapy Vector Capacity and Capability. London: Department of Health: 2007.
65. Hagstrom JE, Hegge J, Zhang G, et al. A facile nonviral method for delivering genes and siRNAs to skeletal muscle of mammalian limbs. Mol Ther 2004; 10: 386-398.
66. Wells DJ. Opening the floodgates: clinically applicable hydrodynamic delivery of plasmid DNA to skeletal muscle. Mol Ther 2004; 10: 207-208.